These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34127645)

  • 41. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
    Stenlöf K; Cefalu WT; Kim KA; Jodar E; Alba M; Edwards R; Tong C; Canovatchel W; Meininger G
    Curr Med Res Opin; 2014 Feb; 30(2):163-75. PubMed ID: 24073995
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL; Stewart J; Issa M; Lake B; Melis R
    Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.
    Bailey CJ; Gross JL; Hennicken D; Iqbal N; Mansfield TA; List JF
    BMC Med; 2013 Feb; 11():43. PubMed ID: 23425012
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives.
    Bonora E
    Int J Clin Pract Suppl; 2002 Jul; (129):5-11. PubMed ID: 12166607
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation.
    Fujioka K; Pans M; Joyal S
    Clin Ther; 2003 Feb; 25(2):515-29. PubMed ID: 12749511
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influence of Fasting Plasma Glucose Targets on Glycemic Variability in Chinese Participants With Type 2 Diabetes: A Post Hoc Analysis of the FPG GOAL Trial (BEYOND III).
    Li L; Yang T; Xue Y; Ruan P; Du J; Li Y; Zhang X; Cui N; Yang W
    Adv Ther; 2022 Jan; 39(1):421-429. PubMed ID: 34757600
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.
    Jadzinsky M; Pfützner A; Paz-Pacheco E; Xu Z; Allen E; Chen R;
    Diabetes Obes Metab; 2009 Jun; 11(6):611-22. PubMed ID: 19515181
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial.
    Meneilly GS; Roy-Duval C; Alawi H; Dailey G; Bellido D; Trescoli C; Manrique Hurtado H; Guo H; Pilorget V; Perfetti R; Simpson H;
    Diabetes Care; 2017 Apr; 40(4):485-493. PubMed ID: 28188240
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial.
    Feig DS; Donovan LE; Zinman B; Sanchez JJ; Asztalos E; Ryan EA; Fantus IG; Hutton E; Armson AB; Lipscombe LL; Simmons D; Barrett JFR; Karanicolas PJ; Tobin S; McIntyre HD; Tian SY; Tomlinson G; Murphy KE;
    Lancet Diabetes Endocrinol; 2020 Oct; 8(10):834-844. PubMed ID: 32946820
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone.
    Wang W; Ning G; Ma J; Liu X; Zheng S; Wu F; Xu L; O'Neill EA; Fujita KP; Engel SS; Kaufman KD; Shankar RR
    Curr Med Res Opin; 2017 Apr; 33(4):693-699. PubMed ID: 28035868
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.
    Yang W; Xing X; Lv X; Li Y; Ma J; Yuan G; Sun F; Wang W; Woloschak M; Lukashevich V; Kozlovski P; Kothny W;
    J Diabetes; 2015 Mar; 7(2):174-81. PubMed ID: 24823599
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials].
    Guo XH; Feng ZK; Xu LH
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):588-594. PubMed ID: 28789492
    [No Abstract]   [Full Text] [Related]  

  • 54. A double-masked placebo-controlled trial assessing effects of various doses of BTS 67,582, a novel insulinotropic agent, on fasting hyperglycemia in NIDDM patients.
    Skillman CA; Raskin P
    Diabetes Care; 1997 Apr; 20(4):591-6. PubMed ID: 9096985
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of fibre additions to flatbread flour mixes for reducing post-meal glucose and insulin responses in healthy Indian subjects.
    Boers HM; MacAulay K; Murray P; Dobriyal R; Mela DJ; Spreeuwenberg MA
    Br J Nutr; 2017 Feb; 117(3):386-394. PubMed ID: 28260548
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials.
    Lajara R; Aguilar R; Hehnke U; Woerle HJ; von Eynatten M
    Clin Ther; 2014 Nov; 36(11):1595-605. PubMed ID: 25236917
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
    Rosenstock J; Wysham C; Frías JP; Kaneko S; Lee CJ; Fernández Landó L; Mao H; Cui X; Karanikas CA; Thieu VT
    Lancet; 2021 Jul; 398(10295):143-155. PubMed ID: 34186022
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Metformin extended-release versus immediate-release: An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes.
    Aggarwal N; Singla A; Mathieu C; Montanya E; Pfeiffer AFH; Johnsson E; Zhao J; Iqbal N; Bailey C
    Diabetes Obes Metab; 2018 Feb; 20(2):463-467. PubMed ID: 28857388
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Equal improvement in glycaemia with lixisenatide given before breakfast or the main meal of the day.
    Ahrén B; Vorokhobina N; Souhami E; Demil N; Ye J; Aronson R
    J Diabetes Complications; 2014; 28(5):735-41. PubMed ID: 25012990
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).
    Yu Pan C; Han P; Liu X; Yan S; Feng P; Zhou Z; Lv X; Tian H; Jin Kui Y; Su B; Shang S; Niemoeller E
    Diabetes Metab Res Rev; 2014 Nov; 30(8):726-35. PubMed ID: 24639432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.